PBM formulary information in wake of mergers sought from FTC by Sen. Wyden.
Executive Summary
FTC INFORMATION ON PBM FORMULARIES AFTER MANUFACTURER MERGERS SOUGHT by Sen. Wyden (D-Ore.) in a June 13 letter to Federal Trade Commission Chairman Robert Pitofsky. "Has the FTC monitored Lilly's market share for therapeutic categories with PCS formularies (including `closed' formularies) for changes since the acquisition?" Wyden asks. "Have you monitored market share fluctuations at other manufacturer-owned PBMs?"